tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Zelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans
Company AnnouncementsZelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans
4d ago
Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position
PremiumCompany Announcements
Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position
1M ago
Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials
PremiumCompany Announcements
Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials
1M ago
Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study
PremiumCompany Announcements
Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study
3M ago
Zelira Therapeutics Strengthens Financial Position and Advances Product Development
PremiumCompany Announcements
Zelira Therapeutics Strengthens Financial Position and Advances Product Development
4M ago
Zelira Therapeutics Converts $3.25M Notes to Equity, Advances Autism Treatment Trials
PremiumCompany AnnouncementsZelira Therapeutics Converts $3.25M Notes to Equity, Advances Autism Treatment Trials
4M ago
Zelira Therapeutics Unveils Strategic Investor Deck
Premium
Company Announcements
Zelira Therapeutics Unveils Strategic Investor Deck
5M ago
Zelira Therapeutics Expands Market Presence with New Securities Quotation
Premium
Company Announcements
Zelira Therapeutics Expands Market Presence with New Securities Quotation
5M ago
Zelira Therapeutics Launches Share Offer to Raise Capital
PremiumCompany Announcements
Zelira Therapeutics Launches Share Offer to Raise Capital
5M ago
Zelira Therapeutics Announces Proposed Issue of 550,000 Securities
PremiumCompany Announcements
Zelira Therapeutics Announces Proposed Issue of 550,000 Securities
5M ago
Zelira Therapeutics Secures $1 Million ATM Funding for Growth
PremiumCompany Announcements
Zelira Therapeutics Secures $1 Million ATM Funding for Growth
5M ago
Zelira Therapeutics Advances Autism Drug Program with FDA Support and Patent Secures
PremiumCompany Announcements
Zelira Therapeutics Advances Autism Drug Program with FDA Support and Patent Secures
6M ago
Zelira Therapeutics Secures $1.15M R&D Tax Incentive Refund to Bolster Operations
PremiumCompany AnnouncementsZelira Therapeutics Secures $1.15M R&D Tax Incentive Refund to Bolster Operations
7M ago
Zelira Therapeutics Advances HOPE® Program with Secured FDA Trial Funding
Premium
Company Announcements
Zelira Therapeutics Advances HOPE® Program with Secured FDA Trial Funding
7M ago
Zelira Therapeutics Secures Fourth Funding Tranche to Advance FDA Trials
Premium
Company Announcements
Zelira Therapeutics Secures Fourth Funding Tranche to Advance FDA Trials
7M ago
Zelira Therapeutics Announces Change in Director’s Interest
PremiumCompany Announcements
Zelira Therapeutics Announces Change in Director’s Interest
7M ago
Zelira Therapeutics Issues Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Issues Convertible Notes
9M ago
Zelira Therapeutics Issues 3.5 Million Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Issues 3.5 Million Convertible Notes
9M ago
Zelira Therapeutics Unveils Growth Plans at Investment Conference
PremiumCompany Announcements
Zelira Therapeutics Unveils Growth Plans at Investment Conference
10M ago
Zelira Therapeutics Secures Shareholder Support at AGM
PremiumCompany AnnouncementsZelira Therapeutics Secures Shareholder Support at AGM
10M ago
Zelira Therapeutics Prepares for 2024 Shareholders Meeting
Premium
Company Announcements
Zelira Therapeutics Prepares for 2024 Shareholders Meeting
10M ago
Zelira Therapeutics’ Financials: Borrowings Boost Cash Flow
Premium
Company Announcements
Zelira Therapeutics’ Financials: Borrowings Boost Cash Flow
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >